FDA-cleared profile

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai) · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Clinical role
Passive-notification triage: it tags each FFDM or DBT screening mammogram for suspicion of at least one suspicious finding, with tags integrated into the hospital PACS or workstation for worklist prioritization; no diagnostic information, and it does not replace image review.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Passive triage only: it cannot remove cases, is not standalone, and output does not annotate original diagnostic images.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Compatible FFDM and DBT DICOM screening examinations; validation population was women aged 35 years and older.
  • Who uses it?Intended users: Radiologists interpreting screening breast examinations.
  • What does the software produce?Output: Suspicious or blank worklist tag, a nondiagnostic Secondary Capture preview and Structured Report.
  • What is its most important limitation?Key limitation: Passive triage only: it cannot remove cases, is not standalone, and output does not annotate original diagnostic images.

Clinical takeaway. Clinical role: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Evidence takeaway. Evidence from the reviewed source record: Retrospective blinded standalone evidence is exact-submission regulatory evidence; vendor marketing numbers were not substituted for FDA endpoints.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Passive-notification triage: it tags each FFDM or DBT screening mammogram for suspicion of at least one suspicious finding, with tags integrated into the hospital PACS or workstation for worklist prioritization; no diagnostic information, and it does not replace image review.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "assist radiologists in prioritizing exams within the standard-of-care image worklist for compatible FFDM and DBT screening mammograms. Utilizing an advanced artificial intelligence algorithm, MammoSightAI analyzes each mammogram and assigns a tag indicating the software’s suspicion of at least one potentially suspicious finding." … "These assigned tags are seamlessly integrated into the hospital PACS or workstation, enabling worklist prioritization or triage to help radiologists focus on the most critical cases first.". Read from the exact FDA decision document on 2026-11-14.

Required input
Compatible FFDM and DBT DICOM screening examinations; validation population was women aged 35 years and older.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Suspicious or blank worklist tag, a nondiagnostic Secondary Capture preview and Structured Report.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Radiologists interpreting screening breast examinations.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Passive triage only: it cannot remove cases, is not standalone, and output does not annotate original diagnostic images.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Retrospective blinded standalone evidence is exact-submission regulatory evidence; vendor marketing numbers were not substituted for FDA endpoints.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Retrospective blinded standalone evidence is exact-submission regulatory evidence; vendor marketing numbers were not substituted for FDA endpoints.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
89.8
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Overall standalone sensitivity; see study context.

Reported specificity
95
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Overall standalone specificity; see study context.

Overall sensitivity

89.8 percent

  • EndpointStandalone suspicious-case classification
  • Population1,019 FFDM and DBT examinations in two retrospective blinded studies
  • Tested versionMammoSightAI

Overall specificity

95 percent

  • EndpointStandalone suspicious-case classification
  • Population1,019 FFDM and DBT examinations in two retrospective blinded studies
  • Tested versionMammoSightAI

MammoSightAI regulatory retrospective blinded studies

  • DesignTwo retrospective blinded standalone studies.
  • Population1,019 exams: 468 FFDM and 551 DBT; women aged 35 years and older.
  • Scopeexact submission
  • Tested versionMammoSightAI
  • Samplen=1019
  • IndependenceIndependence not established

K252954

Reference standard used biopsy/clinical evidence and follow-up categories described in the summary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Compatible FFDM and DBT DICOM screening examinations; validation population was women aged 35 years and older.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · MammoSightAI: K252954 clearance and 510(k) summary

  2. Routing

    Source context, not route validation: Current SaveLife.AI family material describes DICOM integration with PACS/RIS and RadioViewAI/ConnectAI workflows.

    Scope: Product family. Not an exact submission interface guarantee.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · SaveLife.AI AI Suite

  3. AI processing

    Source context, not route validation: The summary describes both on-premises and cloud deployment.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · MammoSightAI: K252954 clearance and 510(k) summary

  4. Returned objects

    Source context, not route validation: Suspicious or blank worklist tag, a nondiagnostic Secondary Capture preview and Structured Report.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · MammoSightAI: K252954 clearance and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Suspicious or blank worklist tag, a nondiagnostic Secondary Capture preview and Structured Report.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · MammoSightAI: K252954 clearance and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The summary describes both on-premises and cloud deployment.
  • Exact FDA submission
  • Checked 2026-09-05
Integration
Current SaveLife.AI family material describes DICOM integration with PACS/RIS and RadioViewAI/ConnectAI workflows.
  • Product family
  • Checked 2026-09-05

Not an exact submission interface guarantee.

Security
The SaveLife.AI trust center (SaveLife.AI is the d/b/a of applicant Neurocareai, Inc.) states HITRUST CSF Certified and HIPAA Compliant status, with a third-party HIPAA audit report and HITRUST CSF assessment report available under NDA; the page also cites FDA 510(k) K241719.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statements, not attestations. The reports are NDA-gated and were not read; the trust center names SaveLife.AI/Neurocareai generally and does not scope the claims to MammoSightAI or any specific release; exact-release scope is not established.

Family DICOM integration

Current AI Suite materials describe PACS/RIS DICOM integration.

product family · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252954
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-05-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored literature or trial candidates; empty metadata snapshots were screened. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-06 - Exact product version
  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Savelife.AI Neurocareai reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not publicly available - checked 2026-09-05 - Exact product version
  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. K252954 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. MammoSightAI model card (K252954)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. MammoSightAI: K252954 clearance and 510(k) summary

    US Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, implementation, evidence

  8. SaveLife.AI AI Suite

    SaveLife.AI - Accessed 2026-09-05

    Scope: product_family_implementation

  9. SaveLife.AI: Security & Trust Center

    Neurocareai, Inc. (d/b/a SaveLife.AI) - Accessed 2026-10-27

    Scope: security

Research history

  1. K252954 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252482

CogNet AI-MT+

Medcognetics, Inc.

Authorized purpose: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-12-11
FDA-cleared K233108

VinDr-Mammo

VinBigData Joint Stock Company

The VinDr-Mammo is a passive notification for prioritization-only, a parallel- workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment. VinDr-Mammo utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam- level. VinDr-Mammo produces an exam-level output to a PACS/Workstation for flagging the suspicious case and allows worklist prioritization. MQSA qualified interpreting physicians are responsible for reviewing each exam on a display approved for use in mammography, according to the current standard of care. VinDr-Mammo device is limited to the categorization of exams, does not provide any diagnostic information beyond triage and prioritization, does not remove images from the interpreting physician’s worklist, and should not be used in lieu of full patient evaluation, or relied upon to make or confirm diagnosis. The VinDr-Mammo device is intended for use with complete 2D FFDM mammography exams acquired using validated FFDM systems only.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-05-23
FDA-cleared K220080

CogNet QmTRIAGE

MedCognetics, Inc.

Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2022-09-29
FDA-cleared K203517

Saige-Q

DeepHealth, Inc.

Authorized purpose: Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2021-04-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history